GSK completes sale of remaining shares in Haleon
GSK plc (LSE/NYSE: GSK) today announced that, further to its announcement on 16 May 2024, GSK has agreed to sell 385,320,110 ordinary shares in Haleon plc (“Haleon“) at a price of 324 pence per share (the “Placing Shares“), raising gross proceeds of approximately £1,248m (the “Placing“).
Following settlement of the Placing, GSK will have fully exited its position and will no longer hold any ordinary shares in Haleon.
Following the successful demerger and premium listing of Haleon as announced on 18 July 2022, GSK initially retained a 12.94% stake in Haleon. As a result of the disposals announced on 12 May 2023, 6 October 2023, 16 January 2024 and 16 May 2024, GSK has since sold a total of 1,195m ordinary shares in Haleon for cumulative gross proceeds of approximately £3.9bn. GSK’s exit of its position in Haleon is consistent with its previous commitments to monetise its holding in a disciplined manner.
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.